This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e157. Learning Objective-Upon completion of this activity, successful learners will be able to identify the risk of cancer progression in unresected intraductal papillary mucinous neoplasms and appropriately manage them according to the natural history of the lesions.
BACKGROUND & AIMS:
It is not clear how best to manage patients with low-risk intraductal papillary mucinous neoplasms (IPMNs) of the pancreas because little is known about IPMN progression to cancer. We sought to determine the cumulative incidence of development of pancreatic cancer in persons with unresected IPMNs (particularly low-risk IPMNs).
METHODS:
We performed a systematic search of the MEDLINE and Embase databases through November 30, 2016 for studies reporting the cumulative incidence of pancreatic cancer in patients with unresected IPMNs or studies that provided data in sufficient detail for us to calculate cumulative incidence values. We categorized patient series as studies on low-risk IPMNs (lesions without main pancreatic duct involvement or mural nodules) or non-low-risk IPMNs. We calculated meta-analytic cumulative incidence values for pancreatic cancer at 1, 3, 5, and 10 years of follow-up by using the inverse variance method and random-effects model.
RESULTS:
Among 1514 articles screened, we identified 10 studies of low-risk IPMNs (n [ 2411) and 9 studies of non-low-risk IPMNs (n [ 825). In studies of low-risk IPMNs, the meta-analytic cumulative incidence values for pancreatic cancer were 0.02% at 1 year (95% confidence interval [CI] , 0.0%-0.23%; I 2 [ 0.0%), 1.40% at 3 years (95% CI, 0.58%-2.48%; I 2 [ 58.5%), 3.12% at 5 years (95% CI, 1.12%-5.90%; I 2 [ 88.0%), and 7.77% at 10 years (95% CI, 4.09%-12.39%; I 2 [ 79.8%). These values were much higher in studies of non-low-risk IPMNs; cumulative incidence values for pancreatic cancer were 1.95% at 1 year (95% CI, 0.0%-5.99%; I 2 [ 84.2%), 5.69% at 3 years (95% CI, 1.10%-12.77%; I 2 [ 89.9%), 9.77% at 5 years (95% CI, 3.04%-19.27%; I 2 [ 92.0%), and 24.68% at 10 years (95% CI, 14.87%-35.90%; I 2 [ 74.3%). The pooled cumulative incidence steadily increased linearly as the follow-up duration increased.
CONCLUSIONS:
In a systematic review and meta-analysis, we found that low-risk IPMNs have almost 8% chance of progressing to pancreatic cancer within 10 years, and higher-risk IPMNs have almost 25% chance of progressing to cancer in 10 years; incidence values increase linearly with time.
Continued long-term surveillance is therefore vital for patients with low-risk IPMNs.
Keywords: Precursor; Tumor; Pancreas; Risk Factor. P ancreatic cancer is one of the leading causes of cancer-related death worldwide and has a poor prognosis, with 5-year survival <10% when all stages are combined and only approximately 25% when only considering localized disease. 1 Hence, it is vital to identify the precursor lesions of pancreatic cancer and appropriately manage them according to their malignant risks and prognostic characteristics. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is a well-defined precursor of pancreatic cancer. 2, 3 IPMNs are increasingly being detected incidentally in most cases because of the widespread use of cross-sectional imaging for evaluating the abdomen. [2] [3] [4] IPMN is currently considered as a quite prevalent condition. Although the true prevalence is not known because many IPMNs are asymptomatic, several patient series comprising adults undergoing abdominal computed tomography or magnetic resonance imaging for non-pancreatic causes reported prevalence ranging from 2.6% to 13.5%. [5] [6] [7] A recent large surgical series also reported that IPMN accounts for the largest fraction of cystic pancreatic neoplasms. 8 Therefore, it is critical to understand and establish a standard regarding how to best manage this disease.
Among the current guidelines on the management of IPMNs, those proposed by the International Association of Pancreatology in 2006 (Sendai) 9 and revised in 2012 (Fukuoka) 10 appear to be most influential. Although there is general agreement regarding the lesions to be managed by immediate surgical resection (IPMNs with enhanced solid components or main pancreatic duct [MPD] diameter !10 mm), the current guidelines are not very clear regarding the management of IPMNs with smaller risks of pancreatic cancer. For instance, although a recent guideline by the American Gastroenterological Association Institute 11 suggests stopping the surveillance for pancreatic cysts smaller than 3 cm without a solid component or a dilated pancreatic duct if there has been no significant change for 5 years, this suggestion is according to very lowquality evidence. Thus, the best management of low-risk IPMN lesions in terms of observation vs surgery and the time frame of such observation, if adopted, remain generally unclear. [12] [13] [14] [15] [16] [17] The current management guidelines are largely based on the strengths of the association between the morphologic features of an IPMN lesion and the likelihood for the lesion to harbor a cancer at a cross-sectional point in time rather than considering the natural history of the lesions and its effect on the future development of pancreatic cancer during subsequent follow-up; in fact, the aforementioned uncertainty regarding the management of low-risk IPMN lesions is likely related to the current lack of firm knowledge on their natural history. 18, 19 Recently, multiple studies have reported on the natural history of unresected IPMNs regarding pancreatic cancer development; however, the results have varied widely. Furthermore, most of the studies included a small number of patients, which could affect the precise estimation of pancreatic cancer incidence. Hence, we believe that it is timely and important to establish a systematic summary regarding the natural history of IPMNs in terms of cancer progression. The findings of such a study would help further improve the current management guidelines and would facilitate a more evidence-based practice. To our knowledge, thus far only 1 study has attempted to metaanalytically determine the risk of cancer progression in low-risk IPMNs through a systematic review. 20 Unfortunately, the study was not conclusive because it had several major methodological weaknesses. The study did not directly collect data regarding the cumulative incidence of pancreatic cancer during follow-up, a parameter that is essential in analyzing the time progression of a disease because it considers follow-up lengths in patients in a time-to-event manner. The study performed a limited literature search by using MEDLINE alone. In addition, it did not look at the actual change in the cumulative incidence of pancreatic cancer over time. Therefore, the natural history of unresected IPMNs has yet to be further clarified through a more properly designed systematic review with meta-analysis. Thus, we aimed to systematically determine the cumulative incidence of pancreatic cancer development in cases of unresected IPMN, with particular emphasis on low-risk IPMN, during a longitudinal follow-up.
Materials and Methods
We followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guideline 21 and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline 22, 23 for this study. Institutional review board approval was not required for this study.
Literature Search Strategy
A thorough search of PubMed MEDLINE, and Embase databases was conducted to identify original research articles that investigated the natural history of unresected IPMNs in terms of pancreatic cancer development. The search query was made to furnish a sensitive literature search to avoid overlooking any relevant articles. Thereafter, we performed a manual evaluation of the searched articles to determine the relevant articles. The following search terms were used: (pancreas OR pancreatic) AND ("intraductal papillary mucinous" OR ipmn) AND (follow-up OR surveillance OR "natural history" OR "natural course") AND (cancer OR malig* OR carcinoma). No beginning date limit was used. We continuously updated the literature search until the end of November 2016. Our search was restricted to human subjects and English-language studies. To expand the search, the bibliographies of articles that were considered valid in the selection process were screened for other potentially suitable articles.
Eligibility Criteria
After removing duplicate articles, articles were reviewed for the following components to determine eligibility: (1) population, patients diagnosed with IPMN; (2) intervention/exposure, follow-up of the lesions without removal; (3) comparison, no requirements; (4) outcome, cumulative incidence of pancreatic cancer during follow-up or availability of sufficient details to draw the incidence in cases where the value was not directly reported; and (5) study design, any type of study. With regard to the diagnosis of IPMN, we considered the diagnosis described in the original studies without any further restrictions. Regarding the criteria for pancreatic cancer, only pancreatic cancer that was confirmed pathologically was considered. We followed the 2000 World Health Organization classification, and both invasive carcinoma and high-grade dysplasia (ie, carcinoma in situ or noninvasive carcinoma) were considered in the present study. Therefore, studies reporting occurrences of any of these 2 entities or a lack thereof were included. Further exclusion criteria were as follows: (1) case reports, review articles, editorials, letters, comments, and conference abstract/proceedings; and (2) studies with overlapping patients and data (in such cases, the duplicated data were included only once in this study by selecting a study that had more comprehensive results for the purpose of this study). Articles were first screened by their titles and abstracts. The full texts of the articles were reviewed after selecting potentially eligible abstracts. Both steps were performed by 2 independent reviewers who had expertise in both the subject matter and the systematic literature review. The 2 reviewers eliminated only those articles that were clearly ineligible. Articles with any degree of ambiguity or that generated differences in opinion between the 2 independent reviewers were reevaluated at a consensus meeting for which a third reviewer (who was also experienced in both the subject matter and the systematic literature review) was invited. We contacted the authors of the original studies through e-mail when the reported information was insufficient.
Data Extraction
The following data were extracted onto a predefined data form: (1) study characteristics, including authors, year of publication, institution, country of origin, time of patient recruitment, and study design (prospective vs retrospective); (2) study patient characteristics, including consecutive vs selective series, age, sex, and the number of patients; (3) IPMN characteristics, including MPD involvement, presence of mural nodules, and cyst size; (4) follow-up information, including follow-up protocol, follow-up length, and lack of follow-up; and (5) study outcomes, including the 1-, 3-, 5-, or 10-year cumulative incidence of pancreatic cancer. We categorized the studies that analyzed prospectively collected registry-type data as prospective studies, regardless of their description in the original articles. The cumulative incidence was directly extracted when specifically reported and was obtained by using Kaplan-Meier curves or was calculated from the follow-up results where this value was not reported. Because the studies that directly reported the cumulative incidence presented the results at 1-, 3-, 5-, or 10-year follow-up time points, the extraction of the cumulative incidence was made for these follow-up time points. Two reviewers independently performed data extraction, and all discrepancies were resolved at a consensus meeting in the presence of a third reviewer.
Assessment of Study Quality
To our knowledge, there is no single formal system to evaluate the quality of longitudinal observational studies on the natural history of a disease. Therefore, we referred to the principles of the GRADE guideline 24, 25 as well as the STROBE guideline 26 and established a customized list of quality-related items specifically for this study according to the basic principles of the guidelines: (1) study design (prospective vs retrospective or unclear), (2) study patients enrollment (consecutive vs selective or unclear series), (3) follow-up protocol (specified vs unspecified), and (4) patient exclusion from analysis because of a lack of follow-up. Studies that had a prospective design, consecutive patient collection, specified follow-up protocol, and no remarkable exclusion of patients because of a lack of follow-up were considered as high-quality studies. Two reviewers independently evaluated the quality, and all discrepancies were resolved at a consensus meeting in the presence of a third reviewer.
Meta-analytic Pooling of the Cumulative Incidence of Pancreatic Cancer
We categorized the included studies into studies of low-risk IPMN and studies of non-low-risk IPMN according to the risk for pancreatic cancer. Although most studies had already described their study patients by using the terms low risk and high risk, we did not directly follow the original descriptions because these risk definitions were heterogeneous. For example, low risk in some studies did not mean a true low risk but indicated a relatively lower risk in those who already met general indication for surgical resection. Therefore, we recategorized the risks by using a uniform definition in the present study. Low risk was defined as a lack of MPD dilatation (ie, MPD diameter smaller than 5 mm when the diameter was specified, or a claim of no MPD involvement according to the original study description) plus a lack of mural nodules. Unlike the Fukuoka 2012 guideline 10 we did not consider cyst size because it was only available in slightly more than half of the studies and also because the importance of cyst size was deemphasized in the guideline. Patients who did not meet these criteria were categorized as non-low risk. The non-low-risk features were somewhat heterogeneous across studies. The pooled cumulative incidence of pancreatic cancer was obtained separately for the 2 risk categories. Studies that contained a small fraction (<10%) of non-low-risk patients 15, [27] [28] [29] were categorized as studies of low-risk IPMN and were primarily pooled together with those studies. Thereafter, we performed a subanalysis for studies that met a clearer definition of low risk, ie, no mixing of non-low-risk patients and a specific mention of MPD diameter smaller than 5 mm. We also performed another subanalysis for the high-quality studies. When an article included a mixture of patients and data that could be extracted separately for low-risk and non-low-risk subsets, the separate data were treated as separate studies for metaanalytic pooling.
For the meta-analysis, we used the inverse variance method to calculate weights; the cumulative incidence and its 95% confidence interval (CI) were obtained by using the restricted maximum-likelihood estimation of randomeffects model. Study heterogeneity was assessed by using the Cochrane Q test and Higgins I 2 statistics. A P value <.10 in the Q test was considered to indicate substantial heterogeneity. I 2 was interpreted as follows as suggested in the literature: 0%À25%, might not be important; 25%À50%, low heterogeneity; 50%À75%, moderate heterogeneity; and 75%À100%, high heterogeneity.
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Analysis of Publication Bias
Publication bias was visually assessed by using a funnel plot, and its statistical significance was tested by using the mixed-effects meta-regression model.
We used R version 3.1.2 (The R Foundation for Statistical Computing, Vienna, Austria) with the metafor package for the analysis.
Results
Literature Search
Our literature search process is illustrated in Figure 1 . A total of 1514 articles were screened after removing the duplicate articles. Of these, 1435 articles were excluded on the basis of their titles and abstracts. Sixty-two articles were excluded after reviewing the full text. Finally, the remaining 17 articles involving a total of 3236 patients were included (Table 1) is not 17 because 2 articles reported results separately for the low-risk and non-low-risk patient groups; hence, these results were considered as separate studies for the meta-analysis. Risk group categorization of subjects in each original study is according to definition of this meta-analysis. Low-risk was defined as lack of MPD dilatation (ie, MPD diameter smaller than 5 mm when specified, or a claim of no MPD involvement according to the original study description) plus lack of mural nodules. Unlike Fukuoka 2012 guideline, 10 cyst size less than 3 cm was not considered. Studies that contained a small fraction (less than 10%) of non-low-risk patients were categorized as studies of low-risk IPMN. b Median age.
9 studies of non-low-risk IPMN 18, 27, [33] [34] [35] [37] [38] [39] 41 involving 825 patients were finally considered. Of the 10 studies of low-risk IPMN, five 13, 18, 32, 40, 42 met the clearer definition of low risk (ie, specific mention of MPD diameter smaller than 5 mm plus a lack of mural nodules in all patients), 4 included a small fraction ( 9%) of patients with non-low-risk IPMNs, and 1 claimed no MPD involvement without specifying the ductal diameter. Most of the 10 studies of low-risk IPMN as defined in this meta-analysis either met 18, 32, 42 or were similar to 15, [27] [28] [29] the low-risk definition according to Fukuoka 2012 guideline, 10 whereas the degree of fulfilling Fukuoka 2012 low-risk definition was unclear in 3 studies. 13, 36, 40 Study Quality Three 15, 36, 42 of the 17 articles fulfilled all the highquality criteria including no exclusion of patients from analysis because of a lack of follow-up. Three other articles 13, 29, 40 excluded 2.1%, 10.5%, and 15.3% of the patients, respectively, from analysis because of a lack of needed follow-up data but otherwise met all the highquality criteria; hence, we still considered these 3 articles as high-quality studies. The further details of study quality are provided in Supplementary Table 1 
Cumulative Incidence of Pancreatic Cancer Development: Meta-analysis
The cumulative incidences at the 1-, 3-, 5-, or 10-year follow-up time points, reported in the 19 individual studies, are summarized in Table 2 .
In the studies of low-risk IPMN, the meta-analytic pooled cumulative incidences of pancreatic cancer at the 1-year, 3-year, 5-year, and 10-year follow-up time points were 0.02% (95% CI, 0.0%-0.23%; I 2 ¼ 0.0%), Figure 2) . No substantial study heterogeneity was observed in terms of the 1-year cumulative incidence; however, there was a moderate or high heterogeneity for the other follow-up time points. The results were similar when only the studies that met the clearer definition of low risk were considered (Table 3 , Supplementary Figure 2) as well as when only the highquality subgroup of the studies of low-risk IPMN were considered (Table 3 , Supplementary Figure 3) . When only the high-quality subgroup of the studies of low-risk IPMN was considered, there was no substantial study heterogeneity for the 3-year incidence (I 2 ¼ 9.6%). In the studies of non-low-risk IPMN, the pooled cumulative incidence of pancreatic cancer was markedly These cumulative incidence values have been obtained through author contact because the original articles only reported a rate that did not consider censored subjects or an overall incidence rate. b Studies that met the clearer definition of low risk, ie, specific mention of MPD diameter smaller than 5 mm plus lack of mural nodule in all patients. c This study investigated cancer development in IPMNs that had not developed pancreatic cancer during the initial 5 years after diagnosis. d Each article reported cumulative incidence of pancreatic cancer separately for low-risk patients and non-low-risk patients. These results were considered as separate studies for the meta-analysis.
higher (approximately at least 3 times) than in the studies of low-risk IPMN, demonstrating 1-year, 3-year, 5-year, and 10-year pooled cumulative incidence of Figure 2 ). The pooled cumulative incidence also showed a linear increase with time. High study heterogeneity was observed at all time points. A subanalysis for high-quality studies was not possible because there was no eligible study.
Publication Bias
In both the low-risk and non-low-risk groups of studies, no significant publication bias was noted (Figure 3 ) except for the 1-year time point in the studies of low-risk IPMN (P ¼ .003).
Discussion
This study showed that cases of both low-risk and non-low-risk IPMNs developed pancreatic cancers in a steady linearly increasing fashion with an increase in the follow-up time. Thus, although low-risk IPMNs showed an overall much lower incidence of pancreatic cancer as compared with non-low-risk IPMNs and had a markedly low absolute incidence of pancreatic cancer at the early follow-up period, the cumulative incidence of pancreatic cancer in low-risk IPMN patients reached 6.26%-7.77% at the 10-year follow-up according to the methods of selecting studies of low-risk IPMN. These cumulative incidence values correspond to annual incidence rates of 0.65%À0.8%/year. A previous meta-analysis fortuitously reported a similar result, 0.7%/year, despite insufficient methodology. 20 To put these rates into context, these are slightly greater than the reported annual risk of esophageal adenocarcinoma in patients who have Barrett's esophagus with low-grade dysplasia, a pooled rate of 0.54% (95% CI, 0.32%À0.76%) according to a recent meta-analysis. 43 What was more uniquely observed in our study is that the annual risk was essentially constant throughout the 10-year followup; therefore, the cumulative incidence of pancreatic cancer in low-risk IPMNs increased in a clear linear fashion over time.
The steady linear increase in pancreatic cancer development over time may have a particular practical implication, because there are currently contrasting opinions regarding the management of patients with low-risk IPMNs. [12] [13] [14] [15] [16] [17] [18] 34 Unlike the current American Gastroenterological Association guideline 11 that recommends stopping surveillance for low-risk pancreatic cysts (ie, smaller than 3 cm without a solid component or a dilated pancreatic duct) after confirming no significant change for 5 years, according to our study results, it would be important to continuously follow patients who have low-risk IPMNs for a longer term and avoid falling into complacency on lesion stability after the early follow-up to avoid overlooking the late development of pancreatic cancer. Because there is a relative paucity of long-term follow-up data published in the literature, a collection of further data on the long-term follow-up of low-risk IPMNs would be beneficial to further confirm our conclusion. Furthermore, a few other factors need to be considered to make the longer surveillance more effective. First, considering that most patients with lowrisk IPMNs would not develop pancreatic cancer even after a long time elapsed, some predictive capability to distinguish those who have and do not have a propensity to ultimately develop pancreatic cancer would make the surveillance more efficient. Unfortunately, such factors or models to predict the natural course of low-risk IPMNs are not yet established, and further investigations are needed in this area. Second, studies on the cost-effectiveness of different surveillance methods would also be worthwhile to find the most effective and affordable strategy for surveillance for a longer term.
We attempted to clearly identify the studies that included patients with low-risk IPMNs according to current practice guidelines. Because of the diversity of the published articles, minor deviations in several studies were unavoidable, including contamination by a small fraction of patients with non-low-risk IPMNs and the claims of no MPD involvement without specifying the ductal diameter. Therefore, we performed a subanalysis of the studies that more clearly fulfilled the low-risk criteria, which showed overall similar results and thus may support the robustness of our study results.
Regarding the publication bias, the statistical analysis indicates that there was a preferential absence of published small studies of low-risk IPMN, which reported the development of pancreatic cancer during the first 1-year follow-up. However, absence of such studies is most likely natural rather than being a publication bias. Such studies, if any, would indicate biased sampling or spurious association because of small sample size.
We tried to account for the large study heterogeneity in the studies of low-risk IPMN at late follow-up time points (ie, 5-year and 10-year) by using the randomeffects model for the meta-analytic synthesis, although some ambiguity in the interpretation of the pooled metaanalytic results may remain. The greater heterogeneity at the later follow-up time points may be due to heterogeneity in the strategy and thoroughness of the long-term follow-up between different institutions and investigators, difference in exact cyst size, difference in patient age, variable sample size and degree of representativeness, and potential varying degrees of miniscule contamination by non-IPMN cysts (considering that the diagnosis of IPMN in the original studies was largely imaging-based, even if the diagnosis must have been rigorously verified by each journal). Unfortunately, further analysis on factors such as cyst size or age could not be performed because the data were not available in analyzable formats or were not available at all. The large heterogeneity observed in the studies of non-low-risk IPMN, which is not the main focus of this study, was expected, because the non-low-risk characteristics varied between studies.
This study had some limitations. First, a collection of further data on the long-term follow-up of low-risk IPMNs from additional primary research studies would be beneficial for making a more solid conclusion. Second, as we analyzed published studies, there was a limitation in understanding the differences between studies regarding censored subjects and how they might affect the results. Third, some studies that reported the development of pancreatic cancer in unresected IPMNs could not be used for analysis because of not enough details needed to draw the cumulative incidence, despite our efforts to contact the authors. Although the manner in which the exclusion of these studies affected the results cannot be definitely determined, a lack of basic information such as the specifics of event time and follow-up length may be an indication of suboptimal quality of the excluded studies in terms of investigating the natural history of a disease.
In conclusion, low-risk IPMNs had a notable cumulative incidence of pancreatic cancer at 10-year follow-up as the incidence steadily increased linearly with the follow-up duration at constant annual incidence rates of 0.65%À0.8%/year. Hence, continued long-term surveillance is vital for low-risk IPMNs.
